The study included 28 patients with pulmonary tuberculosis and a possible postoperative hemoglobin level of less than 120 g/l. For the prevention of postoperative anemia it is used recombinant human erythropoietin alpha and iron (III) hydroxide sucrose complex. Hemoglobin levels were monitored for 4 weeks after surgery and it is estimated the need for blood transfusions. Use of recombinant human erythropoietin and iron sucrose in patients with pulmonary tuberculosis increases basic hematological parameters as compared with the control group, and reduces the risk of postoperative anemia.

The study included 28 patients with pulmonary tuberculosis and a possible postoperative hemoglobin level of less than 120 g/l. For the prevention of postoperative anemia it is used recombinant human erythropoietin alpha and iron (III) hydroxide sucrose complex. Hemoglobin levels were monitored for 4 weeks after surgery and it is estimated the need for blood transfusions. Use of recombinant human erythropoietin and iron sucrose in patients with pulmonary tuberculosis increases basic hematological parameters as compared with the control group, and reduces the risk of postoperative anemia.

The basic parameters characterizing the state of iron metabolism in 245 sickly children aged 2-5 years have been studied. The presence of anemia was established in 11%, iron-deficient erythropoiesis in 20,4%, iron depletion in 29,4 % of frequently ill children sickly children. There was performed an analysis of the forms of anemia in frequently ill children. The obtained data on the high prevalence of iron deficiency in frequently ill children are the basis for a detailed examination and optimization of the treatment of these patients.

The study included 22 patients with pulmonary tuberculosis and presumptive hemoglobin level post surgery of less than 120 g/l. For the prevention of postoperative anemia was used the recombinant human erythropoietin alpha and iron (III) hydroxide sucrose complex. Within four weeks level of hemoglobin after surgery and the need for blood transfusions was accessed. Use of recombinant human erythropoietin and iron sucrose in patients with pulmonary tuberculosis increases basic hematological parameters as compared with the control group, and reduces the risk of postoperative anemia.

Problem of prophylaxis and treatment of early anemia of prematurely born infants is still very important. It's related to increase of rate of infants, surviving with very low and extremely low body weight at the time of birth. The purpose of trial was to provide an optimization of scheme of treatment of early anemia with recombinant human erythropoietin (rh-EPO, Recormon). This trial included 94 infants with very low and extremely low body weight at the time if birth. 26 infants was treated with rh-EPO 500 ME/kg once a week, and 33 infants — with rh-EPO 1000 ME/kg once a week, 35 infants was in control group. Rh-EPO was administrated by subcutaneous introduction once a week, from 3–5 day of life during 6 week. All patients receive iron in dose 4 mg/kg daily. As a result, the need in transfusion was decreased 5 times lower in group of children receiving rh-EPO 500 ME/kg weekly compared to control group. Patients, receiving rh-EPO 1000 ME/kg weekly, had no need in hemotransfusions. Key words: premature, early anemia, recombinant human erythropoietin, hemotransfusion. ( Voprosy sovremennoi pediatrii — Current Pediatrics. 2009;8(2): 38-43 )

The absorption of iron regulates accurately the balance of iron in man. Three iron absorption regulators are described, i.e, alimentary regulator, store-regulator, and erythroid-regulator, The enterocyte is a highly specialized cell of the duodenal epithelium, which coordinates the iron uptake and its transport into the body. The survey focuses on proteins and regulation mechanisms functioning in the enterocytes. Heme, ferrous and ferric iron are absorbed by three different methods, Special molecules for the intake, transport (transferring) and storing (ferritin) of iron in a soluble and non-toxic form took shape in the process of evolution, Iron is delivered to a majority of cells after the binding of transferrin with the transferrin receptor on the cell membrane. The delivery and storing of iron in the cell is regulated post-transcription ally by cytoplasmic factor: iron-regulation proteins 1 and 2 (JPR-1 and JPR-2).